Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

BIOยทNYSE

$304.83

+0.14%
HealthcareMedical - Devices

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

At a Glance

Live Snapshot
Market Cap$8.24B
EPS27.8700
P/E Ratio10.94
Earnings Date07/30/2026
3Y-8.0%
5Y+1.0%
10Y+25.0%
3Y-121.0%
5Y-80.0%
10Y+2602.0%
3Y+174.0%
5Y-9.0%
10Y+146.0%
Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. Profit Bridge

BIO ยท NYSE
Revenue2.58B
Cost of Goods Sold (1.24B)
Gross Profit1.34B
Operating Expenses (1.08B)
Operating Income270.50M
Interest Expense (49.00M)
Other Income/Expense725.00M
Pretax Income995.50M
Income Tax (235.60M)
Net Income759.90M
Net Income
759.90M

Profitability Analysis

Gross Margin

52.0%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

10.5%

Acceptable margins but limited operational leverage. Operating expense control is important.

Net Profit Margin

29.4%

Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.

Effective Tax Rate

23.7%

Moderate tax rate typical for most corporations. Represents standard tax burden on profits.

Profitability Insight

Room for improvement: Moderate profitability with opportunities to enhance margins through better cost management or pricing strategy.

Bio-Rad Laboratories, Inc. Income Statement

BIO โ€ข NYSE

Bio-Rad Laboratories, Inc. Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
REVENUE
2.6B
2.6B
2.7B
2.8B
2.9B
2.5B
2.3B
2.3B
2.2B
2.1B
2B
2.2B
2.1B
2.1B
2.1B
1.9B
1.8B
1.8B
1.5B
1.3B
GROSS PROFIT
(1.2B)
(1.2B)
(1.2B)
(1.2B)
(1.3B)
(1.1B)
(1.1B)
(1.1B)
(972.8M)
(930.1M)
(897.8M)
(996.5M)
(954.2M)
(908.2M)
(895.6M)
(835.6M)
(784.4M)
(801.8M)
(669.7M)
(561.4M)
1.3B
1.4B
1.4B
1.6B
1.6B
1.4B
1.3B
1.2B
1.2B
1.1B
1.1B
1.2B
1.2B
1.2B
1.2B
1.1B
999.8M
962.5M
791.4M
712.5M
OPERATING INCOME
(1.1B)
(1.1B)
(1.1B)
(1.1B)
(1.1B)
(1B)
(1B)
(1B)
(1.1B)
(1B)
(955M)
(1B)
(1B)
(896.9M)
(882.7M)
(807.5M)
(765.1M)
(808.3M)
(648.5M)
(562.3M)
(819.9M)
(814M)
(841.7M)
(827.8M)
(877.1M)
(798.8M)
(824.6M)
(833.3M)
(808.9M)
(816.7M)
(762M)
(808.2M)
(798.1M)
(682.9M)
(696.3M)
(635.2M)
(601.5M)
(591.3M)
(508M)
(438.9M)
(256.9M)
(295.9M)
(247.4M)
(256.9M)
(260.6M)
(217.8M)
(202.7M)
(199.2M)
(250.3M)
(205.9M)
(193M)
(220.3M)
(211M)
(214M)
(186.4M)
(172.3M)
(163.6M)
(159.5M)
(140.5M)
(123.4M)
270.5M
269M
337.8M
482.6M
500.3M
421.3M
229.7M
-108.6M
116.7M
53.2M
166.7M
150M
169.5M
264.1M
295.2M
284M
231M
182.9M
135.2M
146.1M
PRE-TAX INCOME
(49M)
(48.9M)
(49.4M)
(38.1M)
(1.6M)
(21.9M)
(23.4M)
(24M)
(23M)
(23.4M)
(21.7M)
(22.1M)
(61.3M)
(51.1M)
(53.1M)
(63.7M)
(47M)
(32.1M)
(31.6M)
(32M)
46.5M
33.1M
51.5M
19.9M
17.3M
-3.7M
7.1M
2.6M
-3.9M
-8.7M
-11.6M
-8.6M
-47.9M
-39.7M
-44.9M
-58.5M
-47M
-32.1M
-31.6M
-32M
725M
-2.6B
-1.2B
-5.2B
4.9B
4.5B
2B
319.4M
-15.4M
-73.9M
-20.9M
-18.4M
-57.1M
-34.3M
-59.4M
-63.7M
-45.2M
-40.1M
-14.4M
-4.1M
995.5M
-2.3B
-850.1M
-4.7B
5.4B
4.9B
2.3B
507.4M
97.8M
41.6M
145.8M
131.6M
112.4M
231.6M
235.8M
220.3M
185.8M
142.8M
120.8M
142M
NET INCOME
(235.6M)
-498.3M
-212.8M
-1.1B
(1.2B)
(1.1B)
(502.4M)
(146.4M)
-16.9M
(13.4M)
(32.8M)
(42.7M)
(34.6M)
(62.3M)
(57.7M)
(33.3M)
(36.7M)
(44.6M)
(26.5M)
(38.8M)
759.9M
-1.8B
-637.3M
-3.6B
4.3B
3.8B
1.8B
361M
114.7M
28.1M
113.1M
88.8M
77.8M
169.2M
178.2M
185.5M
144.6M
89.5M
93M
103.3M

SEC Filings

BIO - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

April 30, 2026
April 30, 2026
2026
10-Q

10-Q 2026 Q1

Q1

April 30, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 24, 2026
April 21, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 25, 2026
April 21, 2026
2026
8-K

8-K 2026

N/A

February 19, 2026
February 19, 2026
2026
10-K

10-K 2025 FY

FY

February 13, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 12, 2026
February 12, 2026
2026
8-K

8-K 2025

N/A

October 29, 2025
October 29, 2025
2025
10-Q

10-Q 2025 Q3

Q3

October 29, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

September 30, 2025
September 29, 2025
2025
Showing 1 to 10 of 369 filings